







Abstract no.: PR. 7

Demographics

(n=42)

Male

Female

Age (years)

Indication

Sex

Intravesical Botox Injection for Detrusor Overactivity: Efficacy and Safety Profile

HHY Lie¹, TT Chun², WPL Hung¹, TF Wong¹, KH Pang², R Na², HL Wong¹, TCT Lai¹, CF Tsang¹, BSH Ho¹, ATL Ng¹ Institutions:

- ¹Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong SAR
- ²Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

Objective:

- Intravesical Botulinum Toxin (Botox) injection is an evidence based treatment options for patient with UUI / OAB symptoms or neuro-urological disorders as suggested by the EAU guidelines.
- Aim of our study is look for the efficacy and safety profile in our locality.

Patients and method:

• Retrospective analysis of patients who had received treatment in our centres (Tung Wah Hospital and Queen Mary Hospital).



Study Period: Jun 2015 – Sep 2023

No. of Patients: 27 No. of Procedures: 42




bladder

Figure 1 Schematic diagram for injection.

Results:

- Majority of the patients (19 patients, 70.4%) experienced improvement of symptoms after treatment.
- Only 8 patients (29.6%) received repeated treatment, the remaining patients opted to continue oral medications and not for further Botox injections.
- Only 1 patient (2.4%) was complicated with febrile UTI requiring readmission, and none of the patients developed hematuria requiring admission nor acute retention of urine.
- Logistic regression analysis did not identify any statistically significant predictive factor for complication.



Mean (range) or

No. (%) of patients

28 (66.7%)

14 (33.3%)

61.5(46 - 85)




Figure 2 Intra-operative view.



78.6%

procedures (33/42) were effective with patients-reported improvement in symptoms



1

procedure (2.4%) only, was associated with Clavien-Dindo grade II complication

Conclusion

 Intravesical Botox injection is a treatment option beneficial for patients with neurogenic or idiopathic detrusor overactivity with excellent safety profile.

28TH ANNUAL SCIENTIFIC MEETING 2023